Core Viewpoint - Huason Pharmaceutical (002907) announced a share reduction plan involving its controlling shareholder and concerted action party, You Hongtao, through both centralized bidding and block trading methods [1] Summary by Category Share Reduction Plan - The company plans to reduce its shares by a total of up to 12.52 million shares, which represents no more than 3% of the total share capital [1] - The reduction will occur through two methods: a centralized bidding method for up to 4.18 million shares (1% of total share capital) and a block trading method for up to 8.35 million shares (2% of total share capital) [1]

每经AI快讯，华森制药（SZ 002907，收盘价：16.36元）10月14日晚间发布公告称，公司于近日收到控 股股东一致行动人游洪涛先生、上海添橙投资管理有限公司－添橙添利一号私募证券投资基金（简 称"添橙添利一号基金"）发来的《关于计划减持公司股份的告知函》。 持有公司约7242万股股份的游洪涛先生计划自本公告披露之日起15个交易日后的3个月内（即2025年11 月6日至2026年2月5日）通过大宗交易方式减持公司股份合计不超过约665万股，占公司总股本的 1.59%。 持有公司约588万股股份的添橙添利一号基金计划自本公告披露之日起15个交易日后的3个月内（即2025 年11月6日至2026年2月5日）通过集中竞价方式减持公司股份不超过约418万股，占公司总股本的1%； 通过大宗交易方式减持公司股份不超过约170万股，占公司总股本的0.41%；合计减持公司股份约588万 股，占公司总股本的1.41%。 游洪涛先生与添橙添利一号基金为公司控股股东一致行动人，本次拟通过集中竞价方式减持公司股份不 超过约418万股，不超过公司总股本的1.00%；拟通过大宗交易方式减持公司股份约835万股，不超过公 司总股本的 ...

华森制药公告，控股股东一致行动人游洪涛计划于2025年11月6日至2026年2月5日通过大宗交易减持不 超过664.98万股，占1.59%；添橙添利一号私募证券投资基金拟于同期限通过集中竞价减持不超417.59 万股，占1.00%，并通过大宗交易减持不超170.21万股，占0.41%，两者合计减持不超过1252.78万股， 占3%。 ...

特别提示： 证券代码：002907 证券简称：华森制药 公告编号：2025- 078 重庆华森制药股份有限公司 关于公司控股股东一致行动人减持股份预披露的公告 公司控股股东一致行动人游洪涛先生、上海添橙投资管理有限公司 －添橙添利一号私募证券投资基金保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到控股股东一致行 动人游洪涛先生、上海添橙投资管理有限公司－添橙添利一号私募证券投资基金 （简称"添橙添利一号基金"）发来的《关于计划减持公司股份的告知函》。 持有公司72,422,000股股份的游洪涛先生计划自本公告披露之日起15个交易日 后的3个月内（即2025年11月6日至2026年2月5日）通过大宗交易方式减持公司股份 合计不超过6,649,826股，占公司总股本的1.59%。 持有公司5,878,000股股份的添橙添利一号基金计划自本公告披露之日起15个 交易日后的3个月内（即2025年11月6日至2026年2月5日）通过集中竞价方式减持公 司股份不超 ...

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of one chemical raw material and one drug, indicating a positive regulatory development for the company [1] Group 1: Product Approvals - The company received a "Chemical Raw Material Re-registration Approval Notice" for the chemical raw material named Povidone Iodine, which is used in various formulations such as Povidone Iodine solution and Povidone Iodine ointment [1] - The company also obtained a "Drug Re-registration Approval Notice" for the drug named Injection Gabexate Mesilate, which is used for the treatment of acute mild (edematous) pancreatitis and can also assist in the treatment of acute hemorrhagic necrotizing pancreatitis [1]

华森制药公告，公司近日收到重庆市药品监督管理局核准签发的1个化学原料药和1个药品的《再注册批 准通知书》。其中，化学原料药聚维酮碘受理号为CYHZ2427221渝，通知书编号为2025R088239，有效 期为24个月，至2030年09月21日。药品注射用甲磺酸加贝酯受理号为CYHZ2427236渝，通知书编号为 2025R089146，规格为0.1g，注册分类为化学药品，药品注册标准编号为YBH09332022，药品批准文号 有效期至2030年09月24日。此次再注册将确保药品的正常生产和销售，短期内不会对经营业绩产生重大 影响。 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-077 重庆华森制药股份有限公司 关于公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监 督管理局（以下简称"市药监局"）核准签发的关于公司 1 个化学原料药的《化 学原料药再注册批准通知书》和 1 个药品的《药品再注册批准通知书》。现将相 关情况公告如下： 一、《再注册批准通知书》主要信息 原 批 准 文 号：国药准字 H50021186 有 效 期：24 个月 通 知 书 有 效 期：至 2030 年 09 月 21 日 审 批 结 论：经审查，同意本品再注册。由于本品长期未生产， 恢复生产前，登记人应按相关文件要求完成有关 工作，并向市药监局提出恢复生产申请，经现场 检查并抽验一批产品合格后，方可上市销售。 | （一）《化学原料药再注册批准通知书》主要信息 | | --- | 化 学 原 料 药 名 称：聚维酮碘 英 文 名 / 拉 丁 名：Povidone Iodine 受 理 号：CYHZ ...

Group 1 - The company hosted an investor relations event on September 25, 2025, attracting participation from 10 institutions, including Shenzhen Beidouxing Space Investment Company [1] - The event included discussions on the company's operating performance, product layout, market development, and production management, aligning with the company's announcements [1] - Key personnel from the company included the Deputy General Manager and Board Secretary, Financial Director, and Securities Affairs Specialists [1] Group 2 - The company's subsidiary, Huason Yingnuo, is responsible for innovative drug development and has transitioned to a clinical-stage biotechnology company [2] - As of 2025, the company has 7 self-initiated innovative drug projects in development, targeting oncology and autoimmune diseases, with one drug currently in clinical trials [2] - In the first half of 2025, the company achieved revenue of 442 million yuan, a year-on-year increase of 5.76%, driven by the approval and successful bidding of chemical generic drugs [2] Group 3 - The company’s five key traditional Chinese medicine products are focused on common and chronic diseases, with 29 authoritative recommendations received [3] - The sales strategy primarily targets public hospitals, with a significant portion of sales occurring in the hospital market, while also expanding into retail pharmacies and e-commerce [3] - The company has four self-developed special medical food projects, with one project already certified and in the market introduction phase [3] Group 4 - The weight loss drug, Quchang Orlistat capsules, is currently in the market introduction phase as part of the company's health product portfolio [4]

Group 1: Company Overview and Performance - The company achieved a revenue of 442 million CNY in the first half of 2025, an increase of 5.76% compared to the same period last year [4] - The net profit attributable to shareholders reached 53.95 million CNY, up 14.27% year-on-year [4] - The growth in revenue was driven by a 29.45% increase in revenue from chemical generic drugs and a 3.52% increase in key traditional Chinese medicine (TCM) products [4] Group 2: Research and Development - The company’s subsidiary, Huason Yingnuo, has seven innovative drug projects in clinical stages, covering various cancers and autoimmune diseases [3] - The innovative drug ORIC-1940 is currently undergoing Phase Ia/Ib clinical trials [3] - The company has successfully integrated with Chengdu Aorui Pharmaceutical, enhancing its R&D capabilities [3] Group 3: Product Development and Market Strategy - The company has five key TCM products that are essential for common and chronic diseases, with sales growth of 3.52% in the first half of 2025 [6][7] - The TCM product Pain Relief Granules saw sales increase by over 30% [7] - The company is focusing on building an academic system for key products and promoting them in clinical guidelines [7] Group 4: Sales Channels and Market Expansion - Approximately 70% of sales are generated from public hospitals, with efforts to expand into retail pharmacies and e-commerce platforms [8] - The company is actively working to increase its market share in outpatient clinics and other healthcare settings [8] Group 5: Special Medical Foods - The global market for special medical foods is approximately 3 billion USD, with China's market at around 7 billion CNY [9] - The company has four self-developed projects in this category and has received regulatory approval for its first special medical food product [11] - The production line for special medical foods is expected to gradually release capacity as new products are launched [11]

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]